Amaurosis Fugax (Transient Vision Loss): Causes, Symptoms, and Treatment

What is Amaurosis Fugax?

Amaurosis fugax (from the Latin amaurosis, meaning “darkening”, and fugax, meaning “fleeting”) is a sudden, transient loss of vision, typically affecting one eye at a time. It is also commonly referred to by clinicians as “transient monocular blindness” (TMB) or “transient monocular visual loss” (TMVL). In its broadest definition, the term encompasses various causes that share a common feature: the acute, temporary onset of monocular (single-eye) blindness that resolves completely, usually within minutes.

Amaurosis fugax is not merely an ophthalmological curiosity; it is a critically important medical warning sign. In clinical practice, it is classified alongside other transient ischemic attacks (TIAs) because it frequently heralds an imminent, potentially devastating ischemic stroke. The transient nature of the vision loss, paradoxically, can create a false sense of reassurance in both patients and, occasionally, in healthcare providers. This can lead to dangerous delays in evaluation and treatment.

The condition demands urgent medical assessment, not because the episode itself causes lasting damage in most cases, but because it signals significant underlying vascular disease that places the patient at high short-term risk of major stroke and other atherosclerotic cardiovascular events.

Epidemiological Context

Amaurosis fugax is uncommon in children and young adults, in whom it tends to have more benign underlying causes. Its prevalence increases substantially with advancing age and the accumulation of cardiovascular risk factors. In the adult population, particularly those over 50 years of age, the vast majority of cases are attributable to thromboembolic events arising from atherosclerotic disease of the carotid arteries or the heart.

---

Causes

The most common cause of amaurosis fugax is a thromboembolic event: the temporary occlusion of one or more arteries supplying blood to the eye or optic nerve, most commonly the central retinal artery or one of its branches, by an embolus (a blood clot or fragment of atherosclerotic plaque that travels through the bloodstream from a more proximal site).

The Thromboembolic Mechanism

To understand how amaurosis fugax occurs, it is helpful to understand the vascular anatomy of the visual system:

• The central retinal artery, a branch of the ophthalmic artery (which in turn arises from the internal carotid artery), is the primary blood supply to the retina. It is an end artery with no significant collateral circulation, meaning that even brief interruption of flow causes rapid retinal ischemia.
• The posterior ciliary arteries (also branches of the ophthalmic artery) supply the choroid (the vascular layer beneath the retina) and the anterior portion of the optic nerve head.
• The ophthalmic artery itself originates from the internal carotid artery, usually just as it passes through the cavernous sinus above the skull base.

In the typical thromboembolic sequence:

1. Atherosclerotic plaque forms at a site of turbulent arterial flow, most commonly at the bifurcation of the common carotid artery in the neck where it divides into the internal and external carotid arteries.
2. A fragment of this plaque, or a clot that has formed on its irregular surface, breaks off and is carried downstream in the blood flow.
3. The embolus travels through the internal carotid artery into the ophthalmic artery and then into the central retinal artery.
4. Because the retinal arterioles are progressively narrower as they branch, the embolus eventually becomes lodged at a bifurcation point where the vessel is too narrow to allow its passage.
5. Blood flow distal to the obstruction is temporarily interrupted, causing retinal ischemia and the sudden onset of visual loss.
6. In most cases, the embolus either dissolves (if it is a fibrin-platelet thrombus) or is pushed onward into a smaller, more peripheral branch, where its effect on vision may be less complete. This allows blood flow to be restored and vision to recover, hence the transient nature of the episode.

When the embolus fails to dissolve and the retinal artery occlusion becomes permanent, the result is permanent monocular blindness (a non-transient retinal artery occlusion), which is a medical emergency requiring immediate intervention.

Atherosclerotic Plaques and Their Formation

An atherosclerotic plaque is a complex pathological deposit that forms within the walls of arteries as a result of chronic endothelial injury and dyslipidemia. Its development involves the accumulation of oxidized LDL cholesterol, inflammatory cells (particularly macrophages), smooth muscle cells, calcium deposits, and fibrous tissue within the arterial intima. The resulting plaque progressively narrows the arterial lumen and, more dangerously, can develop a fibrous cap that is vulnerable to rupture, releasing thrombogenic material into the bloodstream.

Cardiac Sources of Embolism

Not all emboli causing amaurosis fugax originate from the carotid arteries. Cardiac sources are an important and frequently underappreciated cause, including:

• Atrial fibrillation: the most clinically important cardiac risk factor. In AF, the disorganized, ineffective atrial contractions allow blood to stagnate in the left atrium, particularly in the left atrial appendage, promoting thrombus formation. Fragments of these thrombi can embolize to the cerebral and retinal circulations.
• Other cardiac arrhythmias: any condition causing significant reduction in cardiac output or irregular heartbeat may be associated with cardiogenic embolism.
• Valvular heart disease: calcific aortic stenosis, mitral valve prolapse with regurgitation, and prosthetic heart valves are all potential sources of calcific or fibrin emboli.
• Patent foramen ovale (PFO): an interatrial communication present in approximately 25% of adults that can allow paradoxical embolism (venous thrombi crossing from the right to the left circulation, bypassing the pulmonary filter).
• Left ventricular mural thrombus: typically following myocardial infarction with regional wall motion abnormalities.

Major Risk Factors for Thromboembolic Amaurosis Fugax

The cardiovascular risk factor profile for amaurosis fugax closely mirrors that for ischemic stroke and other atherosclerotic cardiovascular events:

• Atrial fibrillation and other cardiac arrhythmias: particularly AF as described above, but also sick sinus syndrome and other arrhythmias causing hemodynamic compromise
• Arterial hypertension: the single most important modifiable risk factor for atherosclerosis and carotid plaque formation
• Diabetes mellitus: accelerates atherosclerosis through multiple mechanisms including endothelial dysfunction, dyslipidemia, and a pro-inflammatory, pro-coagulant state
• Hypercholesterolemia / dyslipidemia: elevated LDL cholesterol is directly causal in atherosclerotic plaque formation
• Tobacco smoking: a powerful, dose-dependent, independent risk factor for carotid atherosclerosis, accelerating plaque formation and increasing plaque vulnerability
• Alcohol abuse: heavy alcohol consumption contributes to hypertension, arrhythmias (particularly AF, known as “holiday heart syndrome”), and coagulopathy
• Cocaine use: causes intense cerebral and retinal vasoconstriction and promotes arterial thrombosis, even in young patients without underlying atherosclerosis
• Family history of stroke: indicates inherited vascular risk
• Age over 50 years: the prevalence of carotid atherosclerosis and its complications rises steeply with age
• Male sex: men have higher absolute cardiovascular risk than premenopausal women of the same age, though this gap narrows after menopause

Less Common and Non-Vascular Causes

In the broader clinical definition of amaurosis fugax, a number of non-atherosclerotic and non-embolic causes must be considered, particularly in younger patients in whom thromboembolic disease is less likely.

• Optic neuritis: inflammation of the optic nerve, most commonly associated with multiple sclerosis. Visual loss in optic neuritis is often more prolonged than typical amaurosis fugax, may be associated with pain on eye movement, and affects a specific visual field pattern consistent with nerve fiber bundle damage.

• Multiple sclerosis: demyelinating plaques affecting the optic nerve or the visual pathways can produce transient visual disturbances.

• Migraine with aura (ocular migraine): migraine-related visual auras can produce positive (fortification spectra, scintillating scotomata) or negative (scotomata, transient monocular or binocular blindness) visual phenomena. Retinal migraine specifically causes transient monocular visual loss. The visual aura of migraine is usually accompanied by other aura symptoms (sensory, speech disturbances) and followed by headache, though this is not invariable.

• Systemic lupus erythematosus (SLE): an autoimmune disease in which immune-mediated vasculitis and antiphospholipid antibody syndrome can cause retinal artery occlusion and transient visual loss.

• Polyarteritis nodosa: a systemic necrotizing vasculitis of medium-sized arteries that can involve the ophthalmic and retinal arteries.

• Giant cell arteritis (temporal arteritis): a large and medium vessel vasculitis almost exclusively affecting individuals over 50 years of age, in which inflammatory occlusion of the posterior ciliary arteries (which supply the optic nerve head) is the most common cause of ischemic optic neuropathy and sudden visual loss in this age group. This diagnosis should be urgently considered in any patient over 50 with transient or persistent visual loss, particularly if accompanied by scalp tenderness, jaw claudication, headache, or elevated inflammatory markers. It is a medical emergency requiring immediate high-dose corticosteroid therapy.

• Brain tumor: intracranial tumors can rarely cause transient visual symptoms by compressing visual pathways or by producing obstructive hydrocephalus and raised intracranial pressure.

• Head trauma: direct orbital or cranial injury can cause transient visual loss through various mechanisms including vitreous hemorrhage, retinal concussion, or traumatic carotid-cavernous fistula.

• Hyperviscosity syndromes: conditions producing markedly increased blood viscosity (polycythemia vera, Waldenström macroglobulinemia, severe anemia) can impair retinal capillary perfusion.

• Vasospasm: rare, but Raynaud-like vasospasm of the retinal arteries has been reported as a cause of transient monocular blindness, particularly in younger women.

The Unifying Pathophysiological Mechanism

Regardless of the specific underlying cause, the final common pathway producing the visual symptoms of amaurosis fugax is hypoperfusion of the retina or optic nerve, a reduction (or complete, temporary interruption) of blood flow sufficient to impair neural function without immediately causing irreversible cell death. When flow is restored before permanent ischemic injury occurs, vision returns to normal. When the ischemia is sufficiently prolonged or severe, permanent visual loss results.

---

Symptoms

The clinical description of amaurosis fugax is characteristically distinctive and, once heard, is difficult to confuse with other causes of visual disturbance:

Onset:

• The vision loss has a sudden onset. Patients typically describe it as occurring instantaneously or within seconds, without any warning.
• A frequently used and diagnostically helpful description is a “grey shade”, “black curtain”, or “dark shadow” descending or ascending across the visual field of the affected eye, as if a blind or curtain were being slowly drawn down (or up, less commonly) over the eye.
• Some patients describe it as if someone switched a light off, or as a “dimming” or “fogging” of vision in the affected eye.

Laterality:

• By definition, amaurosis fugax most commonly affects one eye only (monocular). The importance of establishing monocularity cannot be overstated: the patient should be explicitly asked whether they covered each eye alternately during the episode to confirm that the vision loss was truly unilateral, as binocular visual field defects (which affect the same side of the visual field in both eyes) arise from pathology in the cerebral visual cortex (posterior cerebral hemisphere) rather than in the eye or optic nerve, pointing to an entirely different diagnosis and localization.
• Bilateral episodes (affecting both eyes simultaneously or in rapid succession) are possible but less common; when they occur, a more central (cortical or brainstem) etiology should be considered.

Extent of visual loss:

• The loss may be complete (total blackout of vision in the affected eye) or partial, affecting only a portion of the visual field (e.g., only the upper or lower half, or a quadrant). Partial visual field loss corresponds to occlusion of a branch rather than the main trunk of the central retinal artery.
• Some patients report “altitudinal” visual loss (affecting only the upper or lower half of the visual field of one eye), a pattern highly characteristic of retinal artery branch occlusion or ischemic optic neuropathy.

Pain:

• Amaurosis fugax is characteristically painless. The absence of pain is an important distinguishing feature from conditions such as acute angle-closure glaucoma (which causes severe eye pain) or optic neuritis (which often produces pain on eye movement).

Duration:

• Episodes typically last from a few seconds to several minutes. The median duration is approximately 2–5 minutes in thromboembolic cases.
• Most episodes resolve completely within 1–5 minutes, though episodes lasting up to 30 minutes or longer have been reported.
• Episodes lasting longer than 1 hour should prompt urgent ophthalmic evaluation, as this raises the probability of a non-resolving retinal artery occlusion, a true ophthalmic emergency.

Resolution:

• Complete recovery of normal vision occurs after the episode resolves, which is what distinguishes amaurosis fugax from a permanent retinal artery occlusion.
• The vision returns in a manner that mirrors the onset, which has been described variously as the “curtain lifting”, vision gradually clearing, or simply the sudden return of normal vision.

Recurrence:

• Episodes may be isolated or may recur, sometimes multiple times within hours or days. Recurring episodes signal ongoing thromboembolic activity and are particularly alarming, as each episode represents a potential harbinger of a larger, permanent ischemic stroke.

---

Complications

The most clinically critical complication of amaurosis fugax, and the primary reason it demands urgent medical attention, is the dramatically elevated short-term risk of ischemic stroke.

Stroke Risk

Multiple large prospective studies have consistently demonstrated that transient monocular visual loss carries a stroke risk comparable to or only modestly lower than that of other transient ischemic attacks. The specific risk profile depends on the underlying cause and the presence of high-risk vascular features, but key data points include:

• Studies of untreated patients with symptomatic severe carotid stenosis (≥70% narrowing) have shown that the majority will develop a major ischemic stroke within 12 months if the stenosis is not treated.
• The highest-risk period is immediately after the TIA or amaurosis fugax: approximately 10–15% of patients with a TIA (including amaurosis fugax) will have a stroke within 3 months, with roughly half of these strokes occurring within the first 48 hours. This is why amaurosis fugax is considered a medical emergency requiring same-day specialist evaluation.
• Risk stratification tools such as the ABCD² score (Age, Blood pressure, Clinical features, Duration, Diabetes) are used clinically to estimate the short-term stroke risk and guide the urgency of the diagnostic workup.

Permanent Visual Loss

When the embolus causing amaurosis fugax fails to lyse or move on, the result is a permanent central or branch retinal artery occlusion, which causes a corresponding permanent monocular visual field defect. In cases of central retinal artery occlusion, this leads to near-complete permanent monocular blindness. The retina, like brain tissue, can tolerate only approximately 90–100 minutes of ischemia before permanent photoreceptor death occurs, making the treatment window extremely narrow.

Cardiovascular Events

As an expression of systemic atherosclerotic disease, amaurosis fugax signals elevated risk not only for stroke but for other major adverse cardiovascular events:

• Myocardial infarction: coronary atherosclerosis frequently coexists with carotid atherosclerosis in the same patient
• Peripheral arterial disease
• Cardiovascular death

The identification of amaurosis fugax should therefore prompt not only urgent assessment of the cerebrovascular and ophthalmic systems, but also comprehensive cardiovascular risk assessment and long-term cardiovascular risk factor management.

---

Diagnosis

The diagnostic workup for amaurosis fugax is urgent and should ideally be initiated within hours of the episode. A systematic approach is used, targeting both the immediate cause of the visual loss and the full spectrum of underlying vascular risk factors.

Clinical History and Risk Factor Assessment

The diagnostic process begins with a thorough clinical history, during which the clinician will:

• Characterize the episode precisely: laterality, onset pattern, extent of visual loss (“curtain”, partial, complete), duration, and resolution
• Establish whether the loss was truly monocular (asking the patient whether they covered each eye alternately during the episode)
• Identify any associated symptoms: transient limb weakness or numbness (suggesting concurrent cerebral ischemia), speech disturbance, headache (raising the possibility of giant cell arteritis, subarachnoid hemorrhage, or migraine)
• Assess all cardiovascular risk factors in detail: hypertension, diabetes mellitus, dyslipidemia, smoking history (pack-years), alcohol intake, cardiac history, family history of stroke or early cardiovascular disease, drug use
• Review all current medications, including antiplatelet agents, anticoagulants, oral contraceptives, and vasoconstrictive drugs

Physical Examination

A directed physical examination includes:

Ophthalmological assessment:

• Funduscopy (fundus examination): direct or indirect ophthalmoscopy to examine the retinal vessels and optic disc. In acute retinal artery occlusion, if the patient is examined promptly during the episode, visible cholesterol crystals (Hollenhorst plaques) may be seen as bright, shiny, yellowish fragments at arterial bifurcations. These are pathognomonic of carotid atherosclerotic disease. Retinal pallor (ischemic whitening of the inner retina) with a “cherry-red spot” at the fovea is characteristic of acute central retinal artery occlusion. After resolution of the episode, funduscopy may appear normal.
• Formal visual acuity, visual field assessment, and pupillary reflexes

Cardiovascular examination:

• Auscultation of the carotid arteries: a carotid bruit (abnormal turbulent flow sound) may be heard in the presence of hemodynamically significant carotid stenosis, though its absence does not exclude significant stenosis and its presence is not specific.
• Cardiac auscultation: to detect valvular abnormalities (murmurs), irregular rhythm (AF), or signs of heart failure
• Blood pressure measurement in both arms (a significant difference may suggest subclavian artery disease)
• General vascular examination (peripheral pulses, signs of peripheral arterial disease)

Laboratory Investigations

A comprehensive blood panel is essential to characterize the metabolic and hematological risk profile:

• Complete blood count (CBC): to detect polycythemia (elevated hematocrit increases blood viscosity and thrombotic risk), thrombocytosis, thrombocytopenia, anemia.
• Fasting blood glucose and HbA1c: to diagnose or assess control of diabetes mellitus.
• Lipid profile: total cholesterol, LDL, HDL, triglycerides, to identify dyslipidemia requiring statin therapy
• Coagulation studies: prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) to screen for coagulopathies. Additional testing for thrombophilia (e.g., antiphospholipid antibodies, protein C/S deficiency, factor V Leiden, prothrombin gene mutation) may be considered in younger patients without obvious atherosclerotic risk factors.
• Inflammatory markers: ESR (erythrocyte sedimentation rate) and C-reactive protein (CRP) are critically important in patients over 50. In this age group, a markedly elevated ESR (over 50–100 mm/hour) should raise strong suspicion of giant cell arteritis, which requires emergency high-dose corticosteroid therapy before further investigations are completed to prevent permanent visual loss.
• Renal function, liver function, thyroid function as indicated.
• In selected cases: antinuclear antibodies (ANA), antiphospholipid antibody panel (lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I antibodies) if a systemic autoimmune or hypercoagulable etiology is suspected.

Imaging and Functional Studies

Carotid artery evaluation is the highest priority in most adult patients.

• Carotid duplex ultrasound (carotid Doppler): the primary first-line non-invasive investigation for carotid artery assessment. It provides both anatomical information (plaque morphology, degree of stenosis based on vessel cross-section and lumen reduction) and functional information (blood flow velocities, which correlate with the degree of stenosis). A duplex showing significant carotid stenosis (≥50–70%) in the ipsilateral internal carotid artery is a major finding that directly influences therapeutic decisions.

• CT angiography (CTA) or MR angiography (MRA) of the carotid and cerebral arteries: provide higher-resolution, three-dimensional assessment of the carotid bifurcation, the intracranial vessels, and the aortic arch. CTA is rapid and widely available; MRA avoids radiation and iodinated contrast. These are typically indicated when duplex ultrasound results are equivocal, when surgical intervention is being considered, or when the anatomy is complex.

Brain imaging:

• Brain MRI with diffusion-weighted imaging (DWI): the most sensitive imaging modality for detecting acute cerebral ischemic lesions. DWI can identify areas of acute ischemia within minutes of onset. In TIA/amaurosis fugax, brain MRI may reveal small acute ischemic lesions (confirming ischemic etiology) even when the patient appears clinically recovered. MRI also allows evaluation of the white matter for chronic ischemic changes, old infarcts, and other pathology.

• Brain CT: more widely and rapidly available than MRI, and superior for detecting acute hemorrhage (important for excluding hemorrhagic stroke as a cause). Less sensitive than MRI for detecting small acute ischemic lesions.

Cardiac evaluation is essential for identifying cardioembolic sources.

• 12-lead ECG: immediately identifies atrial fibrillation (the most important cardiac cause of embolism), as well as other arrhythmias, conduction abnormalities, or signs of myocardial ischemia.

• Prolonged cardiac monitoring: because paroxysmal AF may not be present on a single resting ECG, prolonged cardiac rhythm monitoring (24-hour Holter, 48-hour Holter, or longer-term event recorders or implantable loop recorders) is increasingly used to detect intermittent AF.

• Transthoracic echocardiography (TTE) and, in selected cases, transesophageal echocardiography (TEE): TEE provides superior visualization of the left atrial appendage (the primary site of thrombus formation in AF) and can identify intracardiac thrombi, valvular vegetations, patent foramen ovale with bubble (contrast) study, and aortic arch atheroma as potential embolic sources.

---

Treatment

The treatment approach for amaurosis fugax must be individualized based on the identified underlying cause, the patient’s overall cardiovascular risk profile, and the degree of carotid stenosis. The overarching therapeutic goals are:

1. Preventing stroke and other major cardiovascular events (the primary and most urgent priority)
2. Treating the specific underlying cause of the embolic or ischemic event
3. Aggressively modifying all reversible vascular risk factors
4. Promoting long-term lifestyle changes that reduce cardiovascular risk

Urgent Medical Management

Antiplatelet therapy:

In patients with amaurosis fugax attributable to atherosclerotic thromboembolic disease (i.e., those not in AF or with other indications for anticoagulation), antiplatelet therapy is a cornerstone of treatment:

• Aspirin (75–325 mg daily): the standard first-line antiplatelet agent, substantially reducing the risk of recurrent stroke and other atherosclerotic cardiovascular events.
• Clopidogrel (75 mg daily): an alternative antiplatelet agent for patients who are aspirin-intolerant, or as an addition to aspirin in selected high-risk patients (dual antiplatelet therapy, DAPT, for a limited period).
• Aspirin plus dipyridamole: a validated combination with established efficacy in secondary stroke prevention.

Anticoagulation for cardioembolic sources:

In patients with atrial fibrillation or other identified cardioembolic sources, anticoagulation (rather than antiplatelet therapy) is the appropriate treatment to prevent further embolic events:

• Direct oral anticoagulants (DOACs), such as apixaban, rivaroxaban, dabigatran, and edoxaban, are preferred over warfarin in non-valvular AF due to their superior safety profile and comparable or superior efficacy.
• Warfarin with INR monitoring remains indicated for certain specific indications (mechanical heart valves, certain rheumatic valve diseases, some thrombophilias).

Cardiovascular Risk Factor Management

Antihypertensive therapy:

Blood pressure control is essential, as hypertension is the single most important modifiable risk factor for both carotid atherosclerosis and ischemic stroke. Target blood pressure is generally < 130/80 mmHg in patients with stroke/TIA risk. Preferred agents include ACE inhibitors, ARBs, and thiazide-like diuretics as first-line options.

Statin therapy (lipid-lowering treatment):

High-intensity statin therapy (e.g., atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) is indicated for all patients with atherosclerotic TIA or stroke, regardless of baseline LDL cholesterol levels. Statins reduce LDL, stabilize atherosclerotic plaques (reducing plaque vulnerability to rupture), and have additional pleiotropic anti-inflammatory and endothelial-protective effects. Target LDL < 70 mg/dL (or < 55 mg/dL in very high-risk patients) is recommended by most current guidelines.

Glycemic control:

In patients with diabetes, optimizing blood glucose control (targeting HbA1c < 7–8% depending on individual patient factors) reduces microvascular complications and contributes to macrovascular risk reduction.

Lifestyle Modifications

Comprehensive lifestyle change is an absolute requirement in the management of amaurosis fugax, and cannot be replaced by or considered inferior to pharmacological treatment:

• Complete and permanent smoking cessation: the single most impactful modifiable lifestyle factor for cardiovascular risk reduction. Every consultation should reinforce the cessation message, and pharmacological cessation aids (varenicline, bupropion, nicotine replacement therapy) should be offered proactively.

• Reduction or elimination of alcohol consumption: heavy alcohol intake raises blood pressure, promotes cardiac arrhythmias, and contributes to cardiomyopathy.

• Regular physical activity: at least 150 minutes per week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) reduces blood pressure, improves lipid profile, aids weight management, improves insulin sensitivity, and reduces overall cardiovascular risk.

• Weight management: achieving and maintaining a healthy body weight reduces blood pressure, improves glycemic control, and favorably modifies the lipid profile.

• Heart-healthy dietary pattern: a Mediterranean diet (rich in vegetables, fruits, whole grains, legumes, nuts, olive oil, and fish; moderate in lean poultry; and low in red meat, processed meat, saturated fats, and added sugars) has the strongest evidence base for cardiovascular risk reduction among dietary patterns. The DASH diet (Dietary Approaches to Stop Hypertension) is an effective alternative, particularly for blood pressure control.

• Cocaine and illicit drug avoidance: cocaine-associated amaurosis fugax requires complete cessation of drug use and often benefits from addiction medicine support.

Carotid Endarterectomy (CEA): Surgical Intervention

In patients with significant ipsilateral carotid stenosis (typically defined as ≥50–70% luminal stenosis, as measured by validated angiographic or ultrasound criteria), carotid endarterectomy (CEA) is a highly effective intervention that dramatically reduces the risk of subsequent ipsilateral ischemic stroke.

What the procedure involves: CEA is a surgical procedure performed under general or regional (cervical block) anesthesia. The surgeon makes an incision in the neck, carefully isolates the common carotid artery and its bifurcation into the internal and external carotid arteries, temporarily clamps the artery, opens it longitudinally (arteriotomy), and physically removes the atherosclerotic plaque from the inner wall of the vessel. The artery is then closed (directly or with a patch graft), blood flow is restored, and the neck is closed.

Evidence base: The benefit of CEA for symptomatic carotid stenosis is supported by landmark randomized controlled trials, such as the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST). These demonstrated that CEA reduces the absolute risk of ipsilateral stroke by approximately 15–17% over 5 years compared to medical therapy alone in patients with ≥70% stenosis. The benefit is greatest when surgery is performed as soon as possible after the TIA/amaurosis fugax, ideally within 48–72 hours of the event, as the risk of early recurrent stroke is highest in the immediate post-event period.

Carotid artery stenting (CAS): Percutaneous transluminal carotid angioplasty and stenting is a less invasive alternative to CEA that may be considered in patients who are high surgical risk candidates (severe cardiopulmonary comorbidities, hostile neck anatomy, prior cervical radiation, contralateral carotid occlusion). Evidence from comparative trials suggests that CEA has a somewhat better safety profile than CAS (particularly regarding peri-procedural stroke), but CAS is a valid option in appropriate patients treated at experienced centers.

Specific Treatment of Non-Atherosclerotic Causes

• Giant cell arteritis: requires immediate high-dose corticosteroids (typically methylprednisolone IV 1g/day for 3 days, then high-dose oral prednisolone). Treatment must not be delayed pending biopsy confirmation, as vision loss from giant cell arteritis is typically irreversible once established.
• Optic neuritis / Multiple sclerosis: managed with neurological evaluation, high-dose IV methylprednisolone (to accelerate recovery), and long-term disease-modifying therapy for MS.
• Migraine-related visual symptoms: managed with standard migraine treatments (triptans for acute attacks, prophylactic agents for frequent episodes).
• Hypercoagulable states / antiphospholipid syndrome: require long-term anticoagulation and specialist haematological management.
• Vasospasm: calcium channel blockers may be helpful.

---

Sources and Bibliography

• Tadi P, Najem K, Margolin E. (2023). Amaurosis Fugax. In: StatPearls. Treasure Island (FL): StatPearls Publishing.
• American Academy of Ophthalmology (AAO). Amaurosis Fugax (Transient Vision Loss). EyeWiki.
• MedlinePlus. Amaurosis Fugax. U.S. National Library of Medicine.
• Rothwell PM, et al. (2004). Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study). The Lancet, 370(9596):1432–1442.
• North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET). (1991). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine, 325(7):445–453.
• Johnston SC, et al. (2007). Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack (ABCD² score). The Lancet, 369(9558):283–292.
• Kernan WN, et al. (2014). Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 45(7):2160–2236.
• Hayreh SS. (2009). Acute retinal arterial occlusive disorders. Progress in Retinal and Eye Research, 30(5):359–394.
• Powers WJ, et al. (2019). Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke, 50(12):e344–e418.